An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Accelerant Holdings, together with its subsidiaries, operates a data-driven risk exchange that connects selected specialty insurance underwriters with risk capital partners.
VERDICT
The label
Markup
read at $13.52
Accelerant Holdings holds its Markup at $13.52.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 165 days
Price
$13.52
Valuation
N/A trailing · 14.65 forward price to earnings
Values screen
FAIL· score 10.0
Beta
N/A
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads AVOID — it trades at roughly a 18% discount to our $15.92 fair value, weak competitive moat, 59.70% revenue growth.
Read at
$13.52
N/A P/E · 14.65 fwd
Our fair value
$15.92
18% discount
Analyst target (avg)
$18.00
+33% to current
Target low $14.00Analyst target rangeTarget high $30.00
▲ current $13.52 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$13.52
you are here
Conservative
$12.60
-7%
Analyst avg
$18.00
+33%
Our fair value
$15.92
+18%
Analyst high
$30.00
+122%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
59.70%
Profit margin
-150.61%
Debt to equity
16.77
Analyst consensus
Buy · 9 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its business activity. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Debt loadInterest-bearing debt is just 0.0% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 0.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Insurance broker fails ethical test before numbers even register
Picture an exchange built to match specialty underwriters with outside capital in places where traditional insurers hesitate. Accelerant Holdings sits at that intersection yet trips our ethical screen on business activity, which alone rules it out regardless of any other metric. The company posts 60% revenue growth but cannot turn that into profit, posting a -151% margin and -243% return on equity, so the growth story never reaches the bottom line.
Forward earnings sit at 14.6 times while the moat remains weak and the shares trade below our fair value with an 18% margin of safety. Nine analysts still carry a buy rating and an $18 median target, yet we pass because the ethical failure overrides any valuation gap or analyst consensus. High growth without positive returns or competitive protection simply does not compensate for the red flag already raised.
Currency, regulatory and execution risks in the Cayman structure add further layers of uncertainty that the weak moat cannot offset. The business model may sound efficient on paper but the combination of losses and the ethical breach leaves no room for consideration. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
ARX trades on the NYSE (the company is based in Cayman Islands). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (9 analysts) rates it buy, with a mean price target of $19. Entered 2026-07-21 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-21Markup$13.52-9.8%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (9 analysts) rates it buy, with a mean price target of $19.
2026-07-18Markup$14.99+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (9 analysts) rates it buy, with a mean price target of $19.
2026-07-17Markup$14.99+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (9 analysts) rates it buy, with a mean price target of $19.
2026-07-03Markup$14.99+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$14.99Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.